

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Currently amended) A method for stimulating bone formation and/or inhibiting bone resorption in humans or animals comprising the administration ~~to a subject in need thereof~~ of a composition comprising oleuropein as active compound to a subject in need thereof who is suffering from unbalanced bone formation/bone resorption ratio.
2. (Previously presented) The method according to claim 1, wherein the composition is a nutritional composition suitable for oral administration.
3. (Withdrawn from consideration) The method according to claim 2 wherein the subject in need thereof is a young individuals in a growth period.
4. (Previously presented) The method according to claim 2, wherein the subject in need thereof seeks to prevent bone loss which occurs with aging.
5. (Previously presented) The method according to claim 2, wherein the subject in need thereof has a disorder associated with unbalanced bone formation-bone resorption ratio or seeks to prevent a disorder associated with unbalanced bone formation-bone resorption ratio.

6. (Withdrawn from consideration) The method according to claim 2, wherein the subject in need thereof has a bone deficiency resulting from a fracture.

7. (Previously presented) The method according to claim 2, wherein the subject in need thereof is suffering from or might suffer from a condition selected from the group consisting of type I or type II osteoporosis, secondary osteoporosis, Paget's disease, bone loss or osteolysis observed at the vicinity of a prosthesis, metastatic bone diseases, cancer induced hypocalcemia, multiple myeloma, periodontal diseases or osteoarthritis.

8. (Previously presented) The method according to claim 2, wherein the nutritional composition is selected from the group consisting of food compositions and beverages.

9. (Previously presented) The method according to claim 2, wherein the nutritional composition is a product for animal feeding, in a wet, half-wet, or dry form.

10. (Previously presented) The method according to claim 2, wherein the oleuropein or derivative thereof is an extraction product from a plant belonging to the *Oleaceae* family.

11. (Previously presented) The method according to claim 10, wherein the extraction product is a product extracted from the stems, the leaves, the fruits or the stones of a plant belonging to the *Oleaceae* family.

12. (Previously presented) The method according to claim 10, wherein the plant belonging to the *Oleaceae* family is selected from the group consisting of *olea europaea*, a plant of genus *Ligustrum*, a plant of genus *Syringa*, a plant of genus *Fraxinus*, a plant of genus *Jasminum*, and a plant of genus *Osmanthus*.

13. (Previously presented) The method according to claim 10, wherein the extraction product is an olive oil or an oleuropein rich extract olive oil or leaves.

14. (Previously presented) The method according to claim 2, wherein the nutritional composition is orally administered daily in an amount ranging from 0.01 to 200 mg of the oleuropein or derivative thereof.

15. (Withdrawn from consideration) A nutritional composition for stimulating bone formation and/or inhibiting bone resorption, which comprises oleuropein or a derivative thereof.

16. (Previously presented) The method according to claim 1, wherein the composition is a human or animal pharmaceutical composition.

17. (Withdrawn from consideration) The method according to claim 16, wherein the subject in need thereof is a young individual in a the growth period.

18. (Previously presented) The method according to claim 16, wherein the subject in need thereof seeks to prevent bone loss that occurs with aging (ostopenia).

19. (Previously presented) The method according to claim 16, wherein the subject in need thereof has a pathology associated with an unbalanced bone formation-bone resorption ratio or seeks to prevent a pathology associated with an unbalanced bone formation-bone resorption ratio.

20. (Withdrawn from consideration) The method according to claim 16, wherein the subject in need thereof has a bone deficiency resulting from a fracture.

21. (Previously presented) The method according to claim 16, wherein the subject in need thereof is suffering from or might suffer from a condition selected from the group consisting of type I or type II osteoporosis, secondary osteoporosis, Paget's disease, bone loss or osteolysis observed at the vicinity of a prosthesis, metastatic bone diseases, cancer induced hypercalcemia, multiple myeloma, periodontal diseases or osteoarthritis.

22. (Previously presented) The method according to claim 16, wherein the pharmaceutical composition is in a suitable form for oral, parenteral, intramuscular or intravenous administration.

23. (Previously presented) The method according to claim 16, wherein the pharmaceutical composition is suitable for a daily oral administration in an amount ranging from 0.01 to 200 mg of the oleuropein or derivative thereof.

24. (Withdrawn from consideration) A human or animal pharmaceutical composition for stimulating bone formation and/or for inhibiting bone resorption, comprising oleuropein or a derivative thereof.

25. (Previously presented) The method according to claim 8, wherein the nutritional composition is selected from the group consisting of fruit juices, vegetable juices, oils, butters, margarines, vegetal fats, canned foods, soups, milk-based-foods, ice creams, cheeses, baked products, puddings, confectionary products, cereal bars, breakfast cereals, condiments, and seasoning products.

26. (Previously presented) The method according to claim 25, wherein the nutritional composition is selected from the group consisting of tuna fish in oil, yogurts, cottage cheese, oil-kept cheeses, bread, cookies and cakes, spices and dressings.